Daclizumab Experience in Pediatric Heart Transplant

Stopped early

Conditions studied: Congenital Disorders

In brief

The purpose of this study is to examine the outcomes of those who have received Daclizumab as part of their immuno-suppression protocol following heart transplantation. Literature suggests that the time to first rejection episode can be avoided or delayed by using induction therapy.

Key facts

Study ID

NCT00486057

Run by

Children's Healthcare of Atlanta

People needed

30

Starts

2004-08-01

Expected to finish

2007-11-01

Last updated by the study team

2011-11-21

Who can join

Age: any, up to 21. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Status post heart transplant
• Age 0-21 years
• Received Daclizumab as induction therapy

You may not qualify if…

• Those who do not meet inclusion criteria

Where it is running

• Children's Healthcare of Atlanta — Atlanta, Georgia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.